You just read:

Boehringer Ingelheim Announces Enrollment of First Patient in Phase 3 Trial for Lead Hepatitis C Compound

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

Apr 26, 2011, 09:00 ET